NCT04584996: CIRCUS

CIRcular and Non-coding RNAs as Clinically USeful Biomarkers in Pancreaticobiliary Cancers

Status unknown Last updated 8 March 2021

What this trial tests

trial in Pancreatic Cancer in 186 participants. Status unknown.

Timeline

4 October 2020

Primary endpoint
5 October 2021

5 November 2023

Quick facts

Lead sponsor	Royal Surrey County Hospital NHS Foundation Trust
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	186
Start date	4 October 2020
Primary completion	5 October 2021
Estimated completion	5 November 2023
Sites	1 location across United Kingdom

Conditions studied

• Pancreatic Cancer — all drugs for Pancreatic Cancer →
• Biliary Tract Cancer — all drugs for Biliary Tract Cancer →

Sponsor

Royal Surrey County Hospital NHS Foundation Trust

Who can join

18 and older, any sex, with Pancreatic Cancer or Biliary Tract Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Define the circRNA expression profile in PDAC and identify dysregulated circRNA candidates. These will be validated in further tissue samples.
2. Evaluate candidate circRNA Expression in blood (plasma samples) as a clinically relevant diagnostic biomarker; expanding on the primary objective to include other diagnostic features such as specificity, area under the receiver operator curve, positive predictive value and negative predictive value.
3. Explore the expression of candidate circRNAs and related molecules in patient biomaterials (including tissue, blood, bile and biopsy samples) as biomarkers for diagnosis; prognostication; association with clinico-pathologic features and survival outcomes; and their ability to predict/monitor treatment response e.g. surgery and/or chemotherapy.
4. Utilise computer-based analyses to describe the theoretical interactions of candidate circRNAs within the full complement of RNA and related molecules produced by the tumour cells, called the 'transcriptome', in human PDAC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting non-coding RNAs to overcome cancer therapy resistance.
   Chen B, Dragomir MP, Yang C, Li Q, et al · · 2022 · cited 324× · PMID 35418578 · DOI 10.1038/s41392-022-00975-3
2. Going circular: history, present, and future of circRNAs in cancer.
   Pisignano G, Michael DC, Visal TH, Pirlog R, et al · · 2023 · cited 181× · PMID 37587333 · DOI 10.1038/s41388-023-02780-w
3. Exosomal circRNA: emerging insights into cancer progression and clinical application potential.
   Zhang F, Jiang J, Qian H, Yan Y, et al · · 2023 · cited 143× · PMID 37365670 · DOI 10.1186/s13045-023-01452-2
4. Graphene Sensor Arrays for Rapid and Accurate Detection of Pancreatic Cancer Exosomes in Patients' Blood Plasma Samples.
   Yin T, Xu L, Gil B, Merali N, et al · · 2023 · cited 39× · PMID 37470391 · DOI 10.1021/acsnano.3c01812
5. Current clinical trials with non-coding RNA-based therapeutics in malignant diseases: A systematic review.
   Ito M, Miyata Y, Okada M. · · 2023 · cited 33× · PMID 36841158 · DOI 10.1016/j.tranon.2023.101634
6. CircRNA as an Achilles heel of cancer: characterization, biomarker and therapeutic modalities.
   Zhang J, Luo Z, Zheng Y, Duan M, et al · · 2024 · cited 31× · PMID 39127679 · DOI 10.1186/s12967-024-05562-4
7. Emerging roles of circular RNAs in liver cancer.
   Louis C, Leclerc D, Coulouarn C. · · 2022 · cited 25× · PMID 35036887 · DOI 10.1016/j.jhepr.2021.100413
8. The Emerging Value of Circular Noncoding RNA Research in Cancer Diagnosis and Treatment.
   Jagtap U, Anderson ES, Slack FJ. · · 2023 · cited 24× · PMID 36919419 · DOI 10.1158/0008-5472.can-22-3014